Skip to content

MDMA research published in 2014

Page 3 of 4: studies 41 to 60 of 76, newest first. Back to the MDMA overview

Studies

The effects of psilocybin and MDMA on between-network resting state functional connectivity in healthy volunteers

Frontiers in Human Neuroscience May 27, 2014 Leor Roseman, Robert Leech, Amanda Feilding et al. 293 citations

Perturbing a system and observing the consequences is a classic scientific strategy for understanding a phenomenon. Psychedelic drugs perturb consciousness in a marked and novel way and thus are powerful tools for studying its mechanisms. In the present analysis, we measured changes in resting-state functional connectivity (RSFC) between a standard template of different independent components...

Catechol-o-methyltransferase and 3,4-({+/-})-methylenedioxymethamphetamine toxicity.

Toxicological sciences : an official journal of the Society of Toxicology May 2014 Joseph M Herndon, Aram B Cholanians, Lucina E Lizarraga et al.

Metabolism of 3,4-(±)-methylenedioxymethamphetamine (MDMA) is necessary to elicit its neurotoxic effects. Perturbations in phase I and phase II hepatic enzymes can alter the neurotoxic profile of systemically administered MDMA. In particular, catechol-O-methyltransferase (COMT) plays a critical role in determining the fraction of MDMA that is converted to potentially neurotoxic metabolites....

DOI: 10.1093/toxsci/kfu035 (opens in new tab) Full text (opens in new tab) 3,4-±-methylenedioxymethamphetamine Catechol-o-methyltransferase Hyperthermia

Plasma oxytocin concentrations following MDMA or intranasal oxytocin in humans

Psychoneuroendocrinology April 19, 2014 M. Kirkpatrick, Sunday M. Francis, Royce Lee et al. 106 citations

MDMA (±3,4-methylenedioxymethamphetamine, ‘ecstasy’) is reportedly used recreationally because it increases feelings of sociability and interpersonal closeness. Prior work suggests that the pro-social effects of MDMA may be mediated by release of oxytocin. A direct examination of plasma levels of oxytocin after acute doses of oxytocin and MDMA, in the same individuals, would provide further...

Elucidating the neurotoxic effects of MDMA and its analogs.

Life Sciences April 17, 2014 Senthilkumar S Karuppagounder, Dwipayan Bhattacharya, Manuj Ahuja et al.

There is a rapid increase in the use of methylenedioxymethamphetamine (MDMA) and its structural congeners/analogs globally. MDMA and MDMA-analogs have been synthesized illegally in furtive dwellings and are abused due to its addictive potential. Furthermore, MDMA and MDMA-analogs have shown to have induced several adverse effects. Hence, understanding the mechanisms mediating this neurotoxic...

DOI: 10.1016/j.lfs.2014.02.010 (opens in new tab) Full text (opens in new tab) Drugs of abuse MDMA & Analogs Mitochondrial dysfunction Neurotoxicity +1

MDMA alters emotional processing and facilitates positive social interaction

Psychopharmacology April 12, 2014 Margaret C. Wardle, Harriet de Wit 97 citations

±3,4-Methylenedioxymethamphetamine (MDMA, “ecstasy”) produces “prosocial” effects, such as feelings of empathy and closeness, thought to be important to its abuse and its value in psychotherapy. However, it is not fully understood how MDMA alters basic emotional processes to produce these effects, or whether it produces corresponding changes in actual social behavior. Here, we examined how MDMA...

Pharmacology should be at the centre of all preclinical and clinical studies on new psychoactive substances (recreational drugs).

Journal of Psychopharmacology March 27, 2014 Alfred Richard Green, David Nutt

Despite the publication of a substantial body of preclinical and clinical information on recent recreational drugs such as 3,4-methylenedioxymethamphetamine (MDMA, 'ecstasy') and cathinone compounds such as mephedrone there remains a disturbing lack of consensus as to how dangerous these compounds are to the health of the individual and to society in general. This perspective proposes that use...

‘Ecstasy’ as a social drug: MDMA preferentially affects responses to emotional stimuli with social content

Social Cognitive and Affective Neuroscience March 27, 2014 Margaret C. Wardle, Matthew G. Kirkpatrick, Harriet de Wit 52 citations

3,4-Methylenedioxymethamphetamine (MDMA, 'ecstasy') is used recreationally to improve mood and sociability, and has generated clinical interest as a possible adjunct to psychotherapy. One way that MDMA may produce positive 'prosocial' effects is by changing responses to emotional stimuli, especially stimuli with social content. Here, we examined for the first time how MDMA affects subjective...

The preclinical pharmacology of mephedrone; not justMDMAby another name

British Journal of Pharmacology March 24, 2014 Andrew R. Green, Madeleine V. King, Sinead E Shortall et al. 70 citations

The substituted β‐keto amphetamine mephedrone (4‐methylmethcathinone) was banned in the UK in A pril 2010 but continues to be used recreationally in the UK and elsewhere. Users have compared its psychoactive effects to those of 3,4‐methylenedioxymethamphetamine ( MDMA , ‘ecstasy’). This review critically examines the preclinical data on mephedrone that have appeared over the last 2–3 years and,...

Altered energy production, lowered antioxidant potential, and inflammatory processes mediate CNS damage associated with abuse of the psychostimulants MDMA and methamphetamine.

European Journal of Pharmacology March 15, 2014 Luke A. Downey, Jennifer M Loftis

Central nervous system (CNS) damage associated with psychostimulant dependence may be an ongoing, degenerative process with adverse effects on neuropsychiatric function. However, the molecular mechanisms regarding how altered energy regulation affects immune response in the context of substance use disorders are not fully understood. This review summarizes the current evidence regarding the...

DOI: 10.1016/j.ejphar.2014.01.032 (opens in new tab) Full text (opens in new tab) 2-fluoro-2-deoxy-d-glucose pubchem cid 3,4-Methylenedioxy-N-Methylamphetamine MDMA Bioenergetics Cocaine pubchem cid +4

MDMA effects consistent across laboratories

Psychopharmacology March 15, 2014 M. Kirkpatrick, Matthew J. Baggott, John Mendelson et al. 78 citations

Several laboratories have conducted placebo-controlled drug challenge studies with 3,4-methylenedioxymethamphetamine (MDMA), providing a unique source of data to examine the reliability of the acute effects of the drug across subject samples and settings. We examined the subjective and physiological responses to the drug across three different laboratories and investigated the influence of...

Glial cell response to 3,4-(+/-)-methylenedioxymethamphetamine and its metabolites.

Toxicological sciences : an official journal of the Society of Toxicology March 2014 Joseph M Herndon, Aram B Cholanians, Serrine S. Lau et al.

3,4-(±)-Methylenedioxymethamphetamine (MDMA) and 3,4-(±)-methylenedioxyamphetamine (MDA), a primary metabolite of MDMA, are phenylethylamine derivatives that cause serotonergic neurotoxicity. Although several phenylethylamine derivatives activate microglia, little is known about the effects of MDMA on glial cells, and evidence of MDMA-induced microglial activation remains ambiguous. We...

DOI: 10.1093/toxsci/kft275 (opens in new tab) Full text (opens in new tab) 3,4-±-methylenedioxymethamphetamine Metabolites Microglial activation.

MDMA is certainly damaging after 25 years of empirical research: a reply and refutation of Doblin et al. (2014).

Human Psychopharmacology: Clinical and Experimental March 2014 Andrew C. Parrott

Human Psychopharmacology recently published my review into the increase in empirical knowledge about the human psychobiology of MDMA over the past 25 years (Parrott, 2013a). Deficits have been demonstrated in retrospective memory, prospective memory, higher cognition, complex visual processing, sleep architecture, sleep apnoea, pain, neurohormonal activity, and psychiatric status. Neuroimaging...

Increased cortisol levels in hair of recent Ecstasy/MDMA users.

European Neuropsychopharmacology March 1, 2014 Andrew C. Parrott, H. Sands, Lewis Jones et al. 35 citations

Previous research has revealed an acute 8-fold increase in salivary cortisol following self-administrated Ecstasy/MDMA in dance clubbers. It is currently not known to what extent repeated usage impacts upon activity of the hypothalamic-pituitary-adrenal axis over a more prolonged period of time. This study investigated the integrated cortisol levels in 3-month hair samples from recent...

A reconsideration and response to Parrott AC (2013) "Human psychobiology of MDMA or 'Ecstasy': an overview of 25 years of empirical research".

Human Psychopharmacology: Clinical and Experimental March 1, 2014 Rick Doblin, George Greer, Julie Holland et al. 48 citations

Parrott recently published a review of literature on MDMA/ecstasy. This commentary is a response to the content and tenor of his review, which mischaracterizes the literature through misstatement and omission of contrary findings, and fails to address the central controversies in the literature. The review makes several erroneous statements concerning MDMA-assisted psychotherapy, such as...

DOI: 10.1002/hup.2389 (opens in new tab) MDMA Ecstasy Therapeutic potential Controlled therapeutic contexts +6

In abstinent MDMA users the cortisol awakening response is off-set but associated with prefrontal serotonin transporter binding as in non-users

The International Journal of Neuropsychopharmacology February 14, 2014 Vibe G. Frøkjær, David Erritzøe, Klaus K. Holst et al. 19 citations

Serotonergic signaling is considered critical for an appropriate adaptation to stress. We have previously observed that in healthy volunteers, prefrontal serotonin transporter (SERT) binding is positively associated with hypothalamic-pituitary-adrenal (HPA)-axis output in terms of the cortisol awakening response (CAR). Here, we tested (1) if such a correlation persists in a human model of...

DOI: 10.1017/s1461145714000066 (opens in new tab) Full text (opens in new tab) MDMA Serotonin transporter Clinical psychology Receptor

Drug Abuse and Cardiac Problem

Medicine Today February 10, 2014 Mohammad Shafiqur Rahman Patwary, Kazi Abdullah Al Mamun 4 citations

Drug abuse has reached epidemic proportions in many countries including Bangladesh and threatens to overwhelm economic, social, and health care systems. In addition to their effects on the central nervous system, many of these agents induce profound changes in the heart and circulation that are responsible for a significant proportion of drug-related morbidity. Drugs that can affect the...

MDMA decreases the effects of simulated social rejection.

Pharmacology, Biochemistry, and Behavior February 2014 Charles G Frye, Margaret C. Wardle, Greg J Norman et al.

3-4-Methylenedioxymethamphetamine (MDMA) increases self-reported positive social feelings and decreases the ability to detect social threat in faces, but its effects on experiences of social acceptance and rejection have not been determined. We examined how an acute dose of MDMA affects subjective and autonomic responses to simulated social acceptance and rejection. We predicted that MDMA would...

DOI: 10.1016/j.pbb.2013.11.030 (opens in new tab) Full text (opens in new tab) MDMA Cyberball Respiratory sinus arrhythmia Social cognition

"Ecstasy"-induced toxicity in SH-SY5Y differentiated cells: role of hyperthermia and metabolites.

Archives of Toxicology February 2014 Daniel José Barbosa, João Paulo Capela, Renata Silva et al.

3,4-Methylenedioxymethamphetamine (MDMA; "ecstasy") is a recreational hallucinogenic drug of abuse known to elicit neurotoxic properties. Hepatic formation of neurotoxic metabolites is thought to play a major role in MDMA-related neurotoxicity, though the mechanisms involved are still unclear. Here, we studied the neurotoxicity mechanisms and stability of MDMA and 6 of its major human...

Depression, impulsiveness, sleep, and memory in past and present polydrug users of 3,4-methylenedioxymethamphetamine (MDMA, ecstasy).

Psychopharmacology February 2014 Lynn Taurah, Chris Chandler, Geoff Sanders

Ecstasy (3,4-methylenedioxymethamphetamine, MDMA) is a worldwide recreational drug of abuse. Unfortunately, the results from human research investigating its psychological effects have been inconsistent. The present study aimed to be the largest to date in sample size and 5HT-related behaviors; the first to compare present ecstasy users with past users after an abstinence of 4 or more years,...

How MDMA's Pharmacology and Pharmacokinetics Drive Desired Effects and Harms

The Journal of Clinical Pharmacology January 16, 2014 C. Michael White 58 citations

Abstract 3,4‐Methylenedioxymethamphetamine (MDMA) is an agent of abuse that has been used by over 16 million Americans. Increased energy, elevated mood, bonding with others, and psychedelic effects are desired effects while liver damage, extended depressed mood, sexual assault, rhabdomyolysis, serotonin syndrome, multiorgan failure, cardiovascular events, arrhythmias, and death are possible...